Cibinetide (ARA 290; helix B surface peptide) is a novel 11 amino acid peptide with high affinity and selectivity for the IRR. Despite a short plasma half-life, cibinetide triggers sustained biological effects when concentrations exceed the low nanomolar affinity of the receptor. Notably, in a mouse model of diabetic SNFL, daily administration of cibinetide reversed neuronal dystrophy. In neuropathic states the transient receptor potential vanilloid-1 (TRPV1) on channel, a key integrator of nociception and neurogenic inflammation, undergoes upregulation and sensitization in peripheral small nerve fibers and central pain pathways. Recent data demonstrate that cibinetide antagonizes the TRPV1 channel of small nerve fibers and relieves mechanical hypersensitivity.
ARA-290 is a peptide that is derived from erythropoietin (EPO). EPO has been utilized for decades because of its ability to stimulate red blood cell production within bone marrow. It can also alter a patient’s blood pressure, promote cell survival, and create a neuroprotective effect.
While ARA-290 does not stimulate red blood cell production, it does offer pain-relieving and neuroprotective effects. It also has the potential to stimulate wound repair in patients with chronic diabetes, but this property is still being researched.
The full scope of ARA-290s benefits is still being researched. Cependant, it has the potential to decrease the user’s inflammatory pathways through a process known as paracrine signaling. It has also been linked to reduced HbA1c and improved cholesterol numbers. Studies that have produced these results are still in the trial stages.
Perhaps the most appealing possibility for ARA-290 is that it may have the ability to reduce neuropathic symptoms and stimulate natural wound repair processes.
This peptide serves as an exciting treatment option for patients that are dealing with chronic neuropathic pain and diabetes-related ailments. It can also be safely paired with other peptides like BPC-157, which has healing properties.
